Chromosomal Region 11p14.1 is Associated with Pharmacokinetics and Pharmacodynamics of Bisoprolol

References

• Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA. 1988;260(14):2088–2093. doi:10.1001/jama.1988.03410140100032
   PubMed Web of Science ®Google Scholar
• Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315. doi:10.1093/eurheartj/ehv320
   PubMed Web of Science ®Google Scholar
• Leopold G, Pabst J, Ungethum W, Buhring KU. Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist. J Clin Pharmacol. 1986;26(8):616–621. doi:10.1002/j.1552-4604.1986.tb02959.x
   PubMed Web of Science ®Google Scholar
• Rau T, Wuttke H, Michels LM, et al. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin Pharmacol Ther. 2009;85(3):269–272. doi:10.1038/clpt.2008.218
   PubMed Web of Science ®Google Scholar
• van der Wouden CH, Cambon-Thomsen A, Cecchin E, et al. Implementing Pharmacogenomics in Europe: design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. Clin Pharmacol Ther. 2017;101(3):341–358. doi:10.1002/cpt.602
   PubMed Web of Science ®Google Scholar
• Turner RM, Yin P, Hanson A, et al. Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome. J Clin Lipidol. 2017;11(1):204–214. doi:10.1016/j.jacl.2016.12.007
   PubMed Web of Science ®Google Scholar
• Turner RM, Fontana V, Bayliss M, Whalley S, Santoyo Castelazo A, Pirmohamed M. Development, validation and application of a novel HPLC-MS/MS method for the quantification of atorvastatin, bisoprolol and clopidogrel in a large cardiovascular patient cohort. J Pharm Biomed Anal. 2018;159:272–281. doi:10.1016/j.jpba.2018.06.062
   PubMed Web of Science ®Google Scholar
• Hiltunen TP, Donner KM, Sarin AP, et al. Pharmacogenomics of hypertension: a genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs. J Am Heart Assoc. 2015;4(1):e001521. doi:10.1161/JAHA.114.001521
   PubMed Web of Science ®Google Scholar
• Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns. 1999;37(2):113–124. doi:10.1016/S0738-3991(98)00107-4
   PubMed Web of Science ®Google Scholar
• Garren ST. jmuOutlier: Permutation Tests for Nonparametric Statistics. 2018. Available from: http://CRAN.R-project.org/package=jmuOutlier. Accessed March 19, 2022.
   Google Scholar
• Cvan Trobec K, Grabnar I, Kerec Kos M, et al. Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study. Eur J Clin Pharmacol. 2016;72(7):813–822. doi:10.1007/s00228-016-2041-1
   PubMed Web of Science ®Google Scholar
• Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit. 2012;34(4):467–476. doi:10.1097/FTD.0b013e31825c4ba6
   PubMed Web of Science ®Google Scholar
• Delaneau O, Marchini J, Zagury JF. A linear complexity phasing method for thousands of genomes. Nat Methods. 2011;9(2):179–181. doi:10.1038/nmeth.1785
   PubMed Web of Science ®Google Scholar
• Genomes Project C, Auton A, Brooks LD, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68–74. doi:10.1038/nature15393
   PubMed Web of Science ®Google Scholar
• Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 2009;5(6):e1000529. doi:10.1371/journal.pgen.1000529
   PubMed Web of Science ®Google Scholar
• Pruim RJ, Welch RP, Sanna S, et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics. 2010;26(18):2336–2337. doi:10.1093/bioinformatics/btq419
   PubMed Web of Science ®Google Scholar
• Caudle KE, Sangkuhl K, Whirl-Carrillo M, et al. Standardizing CYP2D6 Genotype to Phenotype Translation: consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci. 2020;13(1):116–124. doi:10.1111/cts.12692
   PubMed Web of Science ®Google Scholar
• Elens L, van Gelder T, Hesselink DA, Haufroid V, van Schaik RH. CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics. 2013;14(1):47–62. doi:10.2217/pgs.12.187
   PubMed Web of Science ®Google Scholar
• Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther. 2015;98(1):19–24. doi:10.1002/cpt.113
   PubMed Web of Science ®Google Scholar
• Sanchez Spitman AB, Moes D, Gelderblom H, Dezentje VO, Swen JJ, Guchelaar HJ. Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism. Eur J Clin Pharmacol. 2017;73(12):1589–1598. doi:10.1007/s00228-017-2323-2
   PubMed Web of Science ®Google Scholar
• Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7. doi:10.1186/s13742-015-0047-8
   PubMed Web of Science ®Google Scholar
• Castano-Amores C, Diaz-Villamarin X, Perez-Gutierrez AM, et al. Pharmacogenetic polymorphisms affecting bisoprolol response. Biomed Pharmacother. 2021;142:112069. doi:10.1016/j.biopha.2021.112069
   PubMed Web of Science ®Google Scholar
• Momcilovic S, Milovanovic JR, Jankovic SM, et al. Population Pharmacokinetic Analysis of Bisoprolol in Patients With Acute Coronary Syndrome. J Cardiovasc Pharmacol. 2019;73(3):136–142. doi:10.1097/FJC.0000000000000644
   PubMed Web of Science ®Google Scholar
• Luzier AB, Killian A, Wilton JH, Wilson MF, Forrest A, Kazierad DJ. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther. 1999;66(6):594–601. doi:10.1053/cp.1999.v66.103400001
   PubMed Web of Science ®Google Scholar
• Taguchi M, Nozawa T, Igawa A, et al. Pharmacokinetic variability of routinely administered bisoprolol in middle-aged and elderly Japanese patients. Biol Pharm Bull. 2005;28(5):876–881. doi:10.1248/bpb.28.876
   PubMed Web of Science ®Google Scholar
• Jankovic SM. Pharmacokinetics of selective beta1-adrenergic blocking agents: prescribing implications. Expert Opin Drug Metab Toxicol. 2014;10(9):1221–1229. doi:10.1517/17425255.2014.937702
   PubMed Web of Science ®Google Scholar
• Horikiri Y, Suzuki T, Mizobe M. Pharmacokinetics and metabolism of bisoprolol enantiomers in humans. J Pharm Sci. 1998;87(3):289–294. doi:10.1021/js970316d
   PubMed Web of Science ®Google Scholar
• Nozawa T, Taguchi M, Tahara K, et al. Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol. J Cardiovasc Pharmacol. 2005;46(5):713–720. doi:10.1097/01.fjc.0000184117.76188.68
   PubMed Web of Science ®Google Scholar
• Gong Y, Qiu W, Ning X, et al. CCDC34 is up-regulated in bladder cancer and regulates bladder cancer cell proliferation, apoptosis and migration. Oncotarget. 2015;6(28):25856–25867. doi:10.18632/oncotarget.4624
   PubMedGoogle Scholar
• Geng W, Liang W, Fan Y, Ye Z, Zhang L. Overexpression of CCDC34 in colorectal cancer and its involvement in tumor growth, apoptosis and invasion. Mol Med Rep. 2018;17(1):465–473. doi:10.3892/mmr.2017.7860
   PubMed Web of Science ®Google Scholar
• Boyle AP, Hong EL, Hariharan M, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 2012;22(9):1790–1797. doi:10.1101/gr.137323.112
   PubMed Web of Science ®Google Scholar
• MacArthur J, Bowler E, Cerezo M, et al. The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog). Nucleic Acids Res. 2017;45(D1):D896–D901. doi:10.1093/nar/gkw1133
   PubMed Web of Science ®Google Scholar
• Fagerberg L, Hallstrom BM, Oksvold P, et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics. 2014;13(2):397–406. doi:10.1074/mcp.M113.035600
   PubMed Web of Science ®Google Scholar
• Singh S, Warren HR, Hiltunen TP, et al. Genome-Wide Meta-Analysis of Blood Pressure Response to beta1-Blockers: results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies). J Am Heart Assoc. 2019;8(16):e013115. doi:10.1161/JAHA.119.013115
   PubMed Web of Science ®Google Scholar
• Choi L, Crainiceanu CM, Caffo BS. Practical recommendations for population PK studies with sampling time errors. Eur J Clin Pharmacol. 2013;69(12):2055–2064. doi:10.1007/s00228-013-1576-7
   PubMed Web of Science ®Google Scholar